Axovant Sciences IPO generates $2B+ valuation, NIH program tracks molecules affected by physical activity (Morning Read)
Axovant Sciences with Alzheimer's drug in Phase 3 development had a monster IPO, prompting fears of a biotech bubble.
Axovant Sciences with Alzheimer's drug in Phase 3 development had a monster IPO, prompting fears of a biotech bubble.